Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303) - Concepedia

Concepedia

Publication | Open Access

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)

DOI Full Paper Access

76

Citations

17

References

2021

Year

Jane R. Schwebke, Ryan Sobel, Janet Gersten, Steven A. Sussman, Samuel Lederman, Mark Jacobs, B. Todd Chappell, David Weinstein, Alfred H. Moffett, Nkechi Azie,

Clinical Infectious Diseases

Abstract

Ibrexafungerp provides a promising safe and efficacious oral treatment that mechanistically differs from current azole treatment options for acute VVC.

References

	Year	Citations

Page 1